알료나 콜레스니크

Recent publications · Crossref

5 total works indexed

1. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

   · 2019 · cited 1,870x

2. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

   · 2020 · cited 1,519x

3. Dependence of Nanoparticle Toxicity on Their Physical and Chemical Properties

   · 2018 · cited 980x

4. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

   · 2021 · cited 638x

5. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

   · 2023 · cited 599x

via Crossref · CC0